Filing Flows › Co-Diagnostics (CODX) › Q4 2024
Co-Diagnostics (CODX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
Co-Diagnostics (CODX) reported revenue of $149K for the fourth quarter 2024 (Q4 2024), -96% from a year earlier and -77% from the quarter before.
Co-Diagnostics, Q4 2024: revenue $149K (-96% year over year), net loss $11.0M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $149K | -77% | -96% |
| Operating profit | −$11.9M | — | — |
| Net earnings | −$11.0M | — | — |
| Operating cash flow | −$8.2M | — | — |
What changed
Revenue was $149K in Q4 2024, down 96% year over year and down 77% from the previous quarter.
Operating costs exceeded revenue by $11.9M, an operating margin of -7973.9%. The fastest-growing cost line was General & admin (+32%). The quarter ended with a net loss of $11.0M, wider than the previous quarter's $9.7M loss.
Operating cash flow was −$8.2M. Non-cash charges added back $357K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $73K exceeded it, leaving free cash flow of −$8.3M.
Questions
What was Co-Diagnostics' revenue in the fourth quarter 2024?
Co-Diagnostics (CODX) reported revenue of $149K for the fourth quarter 2024 (Q4 2024), -96% from a year earlier and -77% from the quarter before.
Source: Co-Diagnostics 10-K on SEC EDGAR.